The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology
Mucopolysaccharidosis II (MPS II) is caused by a deficiency of iduronate-2-sulfatase that results in accumulation of glycosaminoglycans (GAG), including heparan sulfate (HS), which is considered to contribute to neuropathology. We examined the efficacy of intracerebroventricular (ICV) enzyme replacement therapy (ERT) of idursulfase-beta (IDS-β) and evaluated the usefulness of HS as a biomarker for neuropathology in MPS II mice. We first examined the efficacy of three different doses (3, 10, and 30 μg) of single ICV injections of IDS-β in MPS II mice. After the single-injection study, its long-term efficacy was elucidated with 30 μg of IDS-β ICV injections repeated every 4 weeks for 24 weeks. The efficacy was assessed by the HS content in the cerebrospinal fluid (CSF) and the brain of the animals along with histologic examinations and behavioral tests. In the single-injection study, the 30 μg of IDS-β ICV injection showed significant reductions of HS content in brain and CSF that were maintained for 28 days. Furthermore, HS content in CSF was significantly correlated with HS content in brain. In the long-term repeated-injection study, the HS content in the brain and CSF was also significantly reduced and correlated. The histologic examinations showed a reduction in lysosomal storage. A significant improvement in memory/learning function was observed in open-field and fear-conditioning tests. ICV ERT with 30 μg of IDS-β produced significant improvements in biochemical, histological, and functional parameters in MPS II mice. Furthermore, we demonstrate for the first time that the HS in the CSF had significant positive correlation with brain tissue HS and GAG levels, suggesting HS in CSF as a useful clinical biomarker for neuropathology.
This is a preview of subscription content, log in to check access.
This study was supported by AnGes MG, Inc. (PHX0143471) and Samsung Medical Center (GFO2170061).
Compliance with ethical standards
Conflict of interest
Young Bae Sohn, Ah-Ra Ko, Mi-ran Seong, Soyeon Lee, Mi Ra Kim, Sung Yoon Cho, Jung-Sun Kim, Makoto Sakaguchi, Takahiro Nakazawa, Motomichi Kosuga, Joo Hyun Seo, Torayuki Okuyama, and Dong-Kyu Jin declared that they have no conflict of interest.
All institutional and national guidelines for the care and use of laboratory animals were followed.
Akiyama K, Shimada Y, Higuchi T et al (2014) Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice. Mol Genet Metab 111:139–146CrossRefGoogle Scholar
Auclair D, Finnie J, White J et al (2010) Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Genet Metab 99:132–141CrossRefGoogle Scholar
Bach G, Eisenberg F Jr, Cantz M, Neufeld EF (1973) The defect in the hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A 70:2134–2138CrossRefGoogle Scholar
Blake KD, Davenport SL, Hall BD et al (1998) CHARGE association: an update and review for the primary pediatrician. Clin Pediatr (Phila) 37:159–173CrossRefGoogle Scholar
Bruyere J, Roy E, Ausseil J et al (2015) Heparan sulfate saccharides modify focal adhesions: implication in mucopolysaccharidosis neuropathophysiology. J Mol Biol 427:775–791CrossRefGoogle Scholar
Calias P, Papisov M, Pan J et al (2012) CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 7:e30341CrossRefGoogle Scholar
Chen L, Elias G, Yostos MP, Stimec B, Fasel J, Murphy K (2015) Pathways of cerebrospinal fluid outflow: a deeper understanding of resorption. Neuroradiology 57:139–147CrossRefGoogle Scholar
Coppa GV, Gabrielli O, Zampini L et al (2015) Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine. Metab Brain Dis 30:1343–1348CrossRefGoogle Scholar
de Ruijter J, Ijlst L, Kulik W et al (2013) Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease. J Inherit Metab Dis 36:271–279CrossRefGoogle Scholar
Garcia AR, Pan J, Lamsa JC, Muenzer J (2007) The characterization of a murine model of mucopolysaccharidosis II (hunter syndrome). J Inherit Metab Dis 30:924–934CrossRefGoogle Scholar
Glimcher SA, Holman DW, Lubow M, Grzybowski DM (2008) Ex vivo model of cerebrospinal fluid outflow across human arachnoid granulations. Invest Ophthalmol Vis Sci 49:4721–4728CrossRefGoogle Scholar
Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12–15CrossRefGoogle Scholar
Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S (2008) Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol 115:547–559CrossRefGoogle Scholar
Hemsley KM, Hopwood JJ (2009) Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol Ther 47(Suppl 1):S118–S123Google Scholar
Higuchi T, Shimizu H, Fukuda T et al (2012) Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol Genet Metab 107:122–128CrossRefGoogle Scholar
Hladky SB, Barrand MA (2014) Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS 11:26CrossRefGoogle Scholar
Jung SC, Park ES, Choi EN, Kim CH, Kim SJ, Jin DK (2010) Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy. Mol Cells 30:13–18CrossRefGoogle Scholar
Kakkis E, McEntee M, Vogler C et al (2004) Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83:163–174CrossRefGoogle Scholar
Lin HY, Lin SP, Chuang CK et al (2009) Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am J Med Genet A 149A:960–964Google Scholar
Maren S (2001) Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 24:897–931CrossRefGoogle Scholar
Muenzer J, Hendriksz CJ, Fan Z et al (2015) A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 18:73–81Google Scholar
Polito VA, Cosma MP (2009) IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am J Hum Genet 85:296–301CrossRefGoogle Scholar
Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP (2010) Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet 19:4871–4885CrossRefGoogle Scholar
Seibenhener ML, Wooten MC (2015) Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp 96:e52434Google Scholar
Sohn YB, Choi EW, Kim SJ et al (2012) Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases. Am J Med Genet A 158A:90–96CrossRefGoogle Scholar
Wilkinson FL, Holley RJ, Langford-Smith KJ et al (2012) Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One 7:e35787CrossRefGoogle Scholar
Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277CrossRefGoogle Scholar